Serum alpha-fetoprotein is the standard clinical biomarker for hepatocellular carcinoma. However, a new study from experts at the Cleveland Clinic shows that other emerging biomarkers, such as ...

α-Fetoprotein (AFP) is a tumour-associated antigen in hepatocellular carcinoma (HCC) and is a target for immunotherapy. However, there is little information on the pattern of CD4 (Th1) and CD8 ...

The C-reactive protein and alpha-fetoprotein in immunotherapy score identified patients with favorable hepatocellular carcinoma disease control and survival, according to a study presented at the ...

If the HCC prevalence rates were more like those seen in most liver clinics, ~5%, the positive predictive value (PPV) of an AFP of 20 ng/mL would be only 41.5%, and even at a cutoff of 400 ng/mL ...

Among patients with screen-detected HCC, nearly half were identified through imaging studies alone (44.6%) or by both imaging and AFP tests (44.7%). The remaining 10.6% had HCC identified solely ...

Hepatocellular carcinoma is a cancer that starts in your liver. ... Unborn babies have high levels of AFP, but it decreases in most people right after birth.

Early detection of hepatocellular carcinoma (HCC) is crucial for improving survival in patients with chronic hepatitis. The GALAD algorithm combines gender (biological sex), age, α-fetoprotein ...

In a new study, alpha-fetoprotein measurement in combination with ultrasound improved surveillance effectiveness in patients with cirrhosis, according to published data in The American Journal of ...

Early detection of hepatocellular carcinoma (HCC) ... The GALAD algorithm combines gender (biological sex), age, α-fetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of AFP ...

Each year, hepatocellular carcinoma is diagnosed in more than half a million people worldwide, including approximately 20,000 new cases in the United States. 1,2 Liver cancer is the fifth most ...

REACH-2 was a randomized, double-blind, placebo-controlled trial that enrolled 292 patients with hepatocellular carcinoma (HCC) who were intolerant to, or had disease progression while on or ...